Tyrosine Kinase Inhibitors: all 10,744 studies that test it
Page 78 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.
- Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective StudyStatus unknownNCT03110484Phase 2
- Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular CarcinomaCompletedNCT03109886Phase 2
- Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter TrialWithdrawnNCT03104335Phase 2
- Apatinib for the Elderly Advanced Gastric CancerCompletedNCT03104283Phase 2
- A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic ArthritisCompletedNCT03101670Phase 2
- A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung CancerStatus unknownNCT03100955Phase 3
- A Phase I Study of TQ-B3139 on Tolerance and PharmacokineticsStatus unknownNCT03099330Phase 1
- Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular CarcinomaStatus unknownNCT03097848Not applicable
- A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck CancersStatus unknownNCT03096184Phase 2
- A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)CompletedNCT03096080Phase 1
- CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT03095040Phase 3
- Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone LymphomaTerminatedNCT03093831Phase 2
- Biomarker-based Study in R/M SCCHNActive, not recruitingNCT03088059Phase 2
- Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03087448Phase 1
- Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast CancerStatus unknownNCT03086785Phase 2
- Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard ChemotherapyCompletedNCT03086538Phase 2
- A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs HerceptinStatus unknownNCT03085368Phase 2/3
- Afatinib in Locally Advanced and Metastatic ChordomaCompletedNCT03083678Phase 2
- A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) MutationsTerminatedNCT03082300Phase 1
- Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT03081494Phase 1
- Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)Status unknownNCT03080805Phase 3
- Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid LeukemiaTerminatedNCT03079505Phase 3
- A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer PatientsCompletedNCT03075462Phase 1
- Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLCStatus unknownNCT03074864Phase 2/3
- "Curcumin" in Combination With Chemotherapy in Advanced Breast CancerCompletedNCT03072992Phase 2
- A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ AdenocarcinomaStatus unknownNCT03071042Phase 1
- Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell TumorActive, not recruitingNCT03069469Phase 1/2
- A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With MyelofibrosisActive, not recruitingNCT03069326Phase 2
- Turmeric and Curcumin on Sebum ProductionCompletedNCT03066791Not applicable
- A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy ParticipantsCompletedNCT03066687Phase 1
- Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.CompletedNCT03066427Phase 2
- Poziotinib in EGFR Exon 20 Mutant Advanced NSCLCTerminatedNCT03066206Phase 2
- A Phase II Study of Apatinib in STS PatientsStatus unknownNCT03064243Phase 2
- A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)CompletedNCT03062943Phase 2
- A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHLStatus unknownNCT03060850Phase 1
- Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)CompletedNCT03059797Phase 2
- A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKIWithdrawnNCT03058094Phase 3
- Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT03054038Phase 1
- Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 TreatmentCompletedNCT03053219Phase 1
- Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung CancerStatus unknownNCT03050411Phase 1
- Bioequivalence Study of Gefitinib Tablets Under Fed ConditionsCompletedNCT03050177Phase 1
- Bioequivalence Study of Gefitinib Tablets Under Fasting ConditionsCompletedNCT03050164Phase 1
- Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid CancerStatus unknownNCT03048877Phase 3
- Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLCCompletedNCT03046992Phase 1/2
- Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)Status unknownNCT03046979Phase 2
- Effect of BMS-986165 on the Pharmacokinetics of RosuvastatinCompletedNCT03044873Phase 1
- Study of Regorafenib in Patients With Advanced Myeloid MalignanciesCompletedNCT03042689Phase 1
- A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 StudyWithdrawnNCT03042013Phase 2
- Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid CancersTerminatedNCT03037645Phase 1/2
- Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell CarcinomaWithdrawnNCT03035630Phase 2
- Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJAStatus unknownNCT03030937Phase 2
- Apatinib and Chemotherapy Sequential Treatment With Cervical CancerStatus unknownNCT03029013Not applicable
- A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer PatientsStatus unknownNCT03026881Phase 1
- A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma MultiformeStatus unknownNCT03025893Phase 2/3
- Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid TumorsCompletedNCT03023319Phase 1
- Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT03021460Phase 1
- Effect of Oral Supplementation With Curcumin in Patients With Proteinuric Diabetic Kidney DiseaseStatus unknownNCT03019848Phase 2
- A Phase I Study of TQ-B3101 on Tolerance and PharmacokineticsStatus unknownNCT03019276Phase 1
- Paediatric Hepatic International Tumour TrialActive, not recruitingNCT03017326Phase 3
- Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for TransplantTerminatedNCT03015792Phase 1
- Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast CancerCompletedNCT03012230Phase 1
- Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid TumorCompletedNCT03009292Phase 1
- Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLCStatus unknownNCT03008109Phase 3
- The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric CancerStatus unknownNCT03007446Phase 2
- A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)Active, not recruitingNCT03006068Phase 3
- Lenvatinib in Second Line Endometrial CarcinomaWithdrawnNCT03005015Phase 2
- Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male ParticipantsCompletedNCT03004768Phase 1
- EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismStatus unknownNCT03002844Phase 2
- Study of Tofacitinib in Refractory DermatomyositisCompletedNCT03002649Phase 1
- Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLCCompletedNCT03001609Phase 1
- Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate CancerCompletedNCT02998242Not applicable
- Ruxolitinib for Steroid-refractory GVHDCompletedNCT02997280Phase 2
- Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)Status unknownNCT02995187Phase 2
- Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTCTerminatedNCT02992340Phase 1/2
- Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLCTerminatedNCT02991651Phase 1
- Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus CarriersStatus unknownNCT02991638Phase 3
- Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular CarcinomaWithdrawnNCT02989870Phase 1
- Apatinib for Advanced Non-squamous Head and Neck CancerStatus unknownNCT02989259Phase 2
- Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular PatientsCompletedNCT02988440Phase 1
- Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaStatus unknownNCT02981745Phase 1/2
- Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung CancerStatus unknownNCT02980809Phase 2
- Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)CompletedNCT02979821Phase 2
- Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade GliomasCompletedNCT02978261Phase 1
- A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid TumoursStatus unknownNCT02977364Phase 1
- Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard TreatmentCompletedNCT02976896Phase 2
- A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT02976116Phase 2
- Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic CancerStatus unknownNCT02975141Phase 1
- Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung CancerTerminatedNCT02973763Phase 1
- A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast CancerStatus unknownNCT02973737Phase 3
- A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CMLWithdrawnNCT02973711Phase 1/2
- Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLLTerminatedNCT02973399Phase 1
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLActive, not recruitingNCT02972840Phase 3
- Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790MStatus unknownNCT02972333Phase 3
- Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.CompletedNCT02971696Phase 3
- Safety and Tolerability Study of K0706 in Subjects With Parkinson's DiseaseCompletedNCT02970019Phase 1
- Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract CarcinomaCompletedNCT02966821Phase 2
- Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial ChemoimmunotherapyTerminatedNCT02966730Early Phase 1
- A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid MalignanciesTerminatedNCT02966171Phase 1
- A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in ChinaCompletedNCT02966093Phase 3
- The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second LineTerminatedNCT02962388Phase 2/3